美国安进狄诺塞麦注射方法

(Denosumab) is a monoclonal antibody drug developed by the American company Amgen that targets the RANKL protein. The drug can competitively bind to RANKL protein with RANK protein and have an effect similar to OPG, thereby inhibiting osteoclast differentiation and activation mediated by the RANKL-RANK-OPG signaling pathway, reducing osteoclast activity, and improving bone mass and quality. In order for the medicine to be fully effective, patients must know the correct way to use it.

Amgen denosumab in the United States should be injected subcutaneously into patients' upper arms, upper thighs, and abdomen by professional medical personnel at 60 mg every six months. While receiving denosumab treatment from Amgen in the United States, you need to take 1000mg of calcium and at least 4001U of vitamin D every day.

Since RANKL protein is also expressed in dendritic cells and T lymphocytes, the inhibitory effect of denosumab may affect the immune system and cause a certain risk of infectious events. In a large 3-year FREEDOM study, the number of adverse events occurring in the denosumab treatment and placebo groups was similar, among which the occurrences of skin eczema (3%), gastrointestinal distension (2.2%), and cellulitis (0.3%) were statistically significant. No significant differences were found in serious adverse reactions such as serious infections, cancer, hypocalcemia, stroke, and cardiovascular events. Studies have shown that as treatment time increases, the incidence of adverse events, especially infectious events, decreases year by year. In longer-term treatment courses (7 to 10 years), higher rates of adverse events were not seen.

As one of the world's largest biopharmaceutical companies, "Amgen" is a leader in the global biopharmaceutical industry. It has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry. As a drug developed by Amgen in the United States in the field of bone metastasis treatment, it has received widespread attention once it was launched.

Recommended hot articles: /newsDetail/87477.html